 continu tumor-infiltr lymphocyt treatment advanc melanoma nation biotherapi studi group trial melanoma metastas patient purpos tumor-infiltr lymphocyt til tumor tissu cell suspens repeat exposur antigen monoclon antibodi moab initi growth success cultur effort cultur therapeut til earli cultur vivo therapi mean day suffici til treatment therapi cyclophosphamid day continu infus day mean day patient infus median patient age year age sixty-seven percent patient men perform statu patient percent patient liver metastas usual toxic respons rate patient confid interv complet respons cell partial respons cell patient til respons author treatment plan difficult costli effect minor patient overal clinic result superior regimen